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H I G H L I G H T S
 We report 95th percentiles of 61 elements in urine samples from occupationally unexposed UK adults.
 Mixed effects modelling was used to quantify inter/intra individual variances for 31 elements.
 Gender and smoking effects were investigated and reported.
 The utility of creatinine correction was generally shown to reduce intra-individual variability.
 Similar results to other larger published studies but differences in some elements were observed.
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A B S T R A C T
Background: levels for 61 elements were established in urine samples collected from 132 occupationally
unexposed UK adults. In this study all elements were determined by inductively coupled plasma–mass
spectrometry, but methods were ‘tailored’ to the elements; in total six analytical methods were
undertaken. For the ﬁrst time in a UK population 95th percentile values are reported for 19 elements for
which there is no available comparison. Repeat urine samples were collected from some individuals and
mixed effects modelling was carried out on the data to give an estimation of variation both between
individuals and within the same individual. The mixed effects modelling was undertaken on 31 of the
61 elements for which there were more than two thirds of data above the LOQ and variations of between
and within individuals are reported. The analysis found that creatinine adjustment of analyte
concentrations was found to be beneﬁcial for 22 of the 31 elements and that smokers were found to
exhibit signiﬁcantly higher cadmium but lower boron than non-smokers. For most elements, the data
compare well with other published data but higher concentrations were observed in this study for
urinary lead, chromium, vanadium and tungsten.
ã 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Human biomonitoring is a widely acknowledged method to
assess human systemic exposure to chemicals both at occupational
and environmental levels (Bevan et al., 2012). Biomonitoring (BM,
biological monitoring) is the measurement of a substance and/or
its metabolites in biological matrices such as blood and urine and it
allows the assessment of exposure from all sources and pathways.
BM can identify new chemical exposures; can be used to monitor
trends and changes in exposure through periodical workplace
measurements; and can establish the distribution of a chemical* Corresponding author. Tel.: +44 1298 218437; fax: +44 1298 218470.
E-mail address: jackie.morton@hsl.gsi.gov.uk (J. Morton).
http://dx.doi.org/10.1016/j.toxlet.2014.08.019
0378-4274/ã 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access a
nd/3.0/).throughout different population groups and areas (Angrer et al.,
2007). However, the interpretation of biological monitoring values
relies on both guidance values and established background
reference values. There are comparatively few occupational
guidance values so background reference values help assess
whether particular exposure levels are higher than would be
normally expected especially in the absence of other data (Hoet
et al., 2013).
In the UK there is a need to update background levels for metals
that are routinely measured for BM to assess occupational
exposures, e.g. mercury, nickel and chromium. There is also a
need to establish current reference values for elements that are
now measured in BM laboratories but for which there is little
published data e.g. vanadium, tungsten and beryllium. In addition,
it would be advantageous to have reference values for rarerrticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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tantalum in mobile phones); in engineered nanoparticles (e.g.
silver in quantum dots); and metals in other technologies
(e.g. scandium in solid oxide fuel cells and neodymium in high
performance magnets) (Du and Graedel, 2011). It is necessary to
establish baseline background levels so that changes over time can
be tracked and to allow an exposure assessment of workers in
these industries and those workers involved in the ‘end of product
life’ recycling industries.
Reference values for many of these elements in the UK
population are limited. In 1998 White and Sabbioni, reported
reference ranges for thirteen elements in 200 non-exposed
persons in the UK (White and Sabbioni,1998) and in 2012 reference
ranges for seventeen elements analysed in 24 h collections from
111 patients from a renal stones clinic in Southampton (Sieniawska
et al., 2012) were reported. In addition, a CEFIC (European chemical
industries association) funded study was reported in 2012 where
436 UK individuals provided urine samples for a range of
background analytes to be measured including two metals,
mercury and cadmium (Bevan et al., 2012). Several European
countries have established human biomonitoring programmes and
networks, such as those in Belgium (Schoeters et al., 2012), France
(Fréry et al., 2011), Czech Republic (Cerna et al., 2007) and
Germany (Schulz et al., 2011, 2007). In the U.S., the ‘The National
Report on Human Exposure to Environmental Chemicals’
(NHANES, 2011) provides an on-going assessment of the exposure
of the U.S. population to environmental chemicals using biological
monitoring. Although this is an extensive and informative study
the utility of the data is restricted because geographic, industrial
and dietary differences exist between the US and the UK and
because the NHANES programme only reports levels for thirteen
elements. There have also been several European studies that have
looked at reference ranges including a recent Belgian study, where
Hoet et al. published a comprehensive list of the reference values
for 26 trace elements in urine samples from 1022 adults (Hoet
et al., 2013). However, as reference values are known to be
inﬂuenced by environment, lifestyle factors and may differ from
countries/regions and if possible they should be established at a
national/regional level (Hoet et al., 2013).
The data reported in this paper contribute to valuable
information on background levels for a wide range of elements
in urine samples from non-occupationally exposed adults. The
sample cohort is not representative of the whole UK population but
this dataset offers information on current levels for the largest
number of elements undertaken in any UK study. This study
measured repeat samples from the cohort of non-occupationally
exposed people to provide an idea of variation of elemental
concentrations both between and within individuals. The samples
were analysed using modern analytical techniques and instru-
mentation with good limits of detection. Each urine sample was
analysed for 61 elements and also for creatinine. Mathematical
modelling was used to investigate the effectiveness of creatinine
adjustment for each element. The elements selected were chosen
for their relevance to both current environmental and occupational
exposures and future potential uses.
2. Material and methods
2.1. Sample collection from non-occupationally exposed individuals.
Anonymous urine samples (n = 280, from 132 individuals) were
collected from staff at the Health and Safety Laboratory (Buxton,
Derbyshire, UK) and their friends/relatives. The samples came from
locations over a 400 mile distance (from Glasgow to Southampton)
but the majority of the samples were collected from people
residing within a 50 mile radius of Buxton. All participatingvolunteers provided informed consent, in accordance with HSG
167 (Health and Safety Executive, 1997). Participants provided
their initials, date of birth and information such as gender, smoking
status, and the date and time of sample collection. Urine samples
were externally posted or hand-collected at HSL. There was no
standardised time duration between collection of sample and lab
receipt/freezing but typically this was less than a week. Samples
were collected in 30 mL polystyrene urine collection bottles
(Sterilin, Newport, UK), and were frozen at 20 C until they
were analysed for creatinine and for the 61 elements of interest.
2.2. Reagents
Ultra purity acids supplied by Romil Ltd., Cambridge, UK.
EDTA (diaminoethanetetracetic acid), and Primar 100 mg/L
multi-elemental ICP–MS standard supplied by Fisher Scientiﬁc,
Loughborough, UK. Rare earths were all supplied in a 10 mg/L
multi-element standard ‘multi element solution 1’ SPEX Certiprep,
Metuchen, NJ, USA. All single standards (including those used as
internal standards) were ICP–MS standards from VWR Interna-
tional, Lutterworth, UK.
2.3. Samples
Urine samples were defrosted at room temperature and mixed
on a rotary mixer for a minimum of 20 min. All urine samples and
urine quality control (QC) samples were diluted either 1 in 20 or
1 in 10 with the speciﬁc diluents and analysed for different
elements using each of the six methods (described in Table 1). The
internal standards were made at the concentrations stated in
Table 1 in the different 1 L acid diluents described and then added
to each sample to dilute accordingly.
2.4. Sample analysis
All sample analysis was undertaken using inductively coupled
plasma–mass spectrometry (ICP–MS). All elements besides beryl-
lium were determined using an XSERIES 2 ICP–MS (Thermo Fisher
Scientiﬁc, Hemel Hempstead, UK). Beryllium was determined on an
ICAP-Q ICP–MS (Thermo Fisher Scientiﬁc, Hemel Hempstead, UK).
The 61 elements were not all measured in the same analysis. The
reason for this is that elements can all react differently in certain acid
solutions or in certain inductively coupled plasma conditions and so
compatible elements were analysed together underan optimised set
of conditions. Six different analytical methods were used where
either sample preparation and/or instrument conditions were
optimised for the suite of elements being analysed. The different
matrices/instrument conditions employed for each analysis and the
elements (and their isotope used) measured by each method are
described in Table 1.
For the Thermo XSERIES 2 ICP–MS the typical normal mode
conditions were as follows: extraction voltage was typically
–100 V, Rf Power 1400 W, focus voltage 12.0 V and nebuliser gas
ﬂow rate (using a Burgener Miramist nebuliser) 0.83 L/min. Dwell
times were 50 ms for each element and 10 ms for internal
standards, with 50 sweeps per replicate and three replicates per
sample. The instrument was tuned on a daily basis to ensure
optimisation. When using the Thermo XSERIES 2 ICP–MS in
collision cell mode, typically using a collision cell gas ﬂow of
3.5 mL/min of 7% hydrogen in helium.
For the ICAP Q ICP–MS the typical normal conditions were as
follows: extraction voltage was typically –120 V, Rf Power 1400 W,
and nebuliser gas ﬂow rate (using a PFA nebuliser) 1.05 L/min.
Dwell times were 1 s for 9Be and 0.05 s for 72Ge, with 20 sweeps per
Table 1
Description of the six methods used to analyse the different suites of elements.
Method Analytical
conditions
Elements Method description
Method 1 (18 elements) Normal mode 7Li (lithium) 88Sr (strontium) Urine samples diluted 20-fold.
Diluent:
1% v/v nitric acid (Romil, UpATM ultra purity acid), 0.04% m/v EDTA.
Internal standards:
10 mg/L–Y In Rh Pt 30 mg/L–Ge
Calibration 0.1–100 mg/L
11B (Boron) 90Zr (zirconium)
27Al (Aluminium) 111Cd (cadmium)
45Sc (scandium) 121Sb (antimony)
59Co (cobalt) 133Cs (caesium)
60Ni (nickel) 137Ba (barium)
65Cu (copper) 205Tl (thallium)
66Zn (zinc) 208Pb (lead)
85Rb (rubidium) 209Bi (bismuth)
Method 2 (10 elements) Collision cell mode 49Ti (titanium) 78Se (selenium) Urine samples diluted 20-fold.
Diluent:
See Method 1
Internal standards:
See Method 1
Calibration 0.1–20 mg/L (Br 2.5–500 mg/L)
51V (vanadium) 79Br (bromine)
52Cr (chromium) 95Mo
(molybdenum)
55Mn (manganese) 118Sn (tin)
75As (Arsenic) 182W (tungsten)
Method 3 (1 element) Normal mode 202Hg (mercury) Urine samples diluted 20-fold.
Diluent:
1% v/v Nitric acid (Romil, UpATM ultra purity acid), 0.01% m/v EDTA, 1 mg/L
gold solution (ICP–MS standard).
Internal Standards:
10 mg/L–Pt
Calibration 0.5–10 mg/L
Method 4 (9 elements) Normal mode 93Nb (niobium) Urine samples diluted 20-fold.
Diluent:
1% v/v hydrochloric acid (Romil, UpATM ultra purity acid.
Internal standards:
10 mg/L–Bi Ho In Sc Tb Y1 mg/L–Tm
Calibration 0.001–2 mg/L
101Ru (ruthenium)
103Rh (rhodium)
107Ag (silver)
125Te (tellurium)
181Ta (tantalum)
189Os (osmium)
193Ir (iridium)
195Pt (platinum)
Method 5 (22 elements) Normal mode 69Ga (gallium) 157Gd (gadolinium) Urine samples diluted 10-fold.
Diluent:
1% v/v nitric acid (Romil, UpATM ultra purity acid),
Internal standards:
1 mg/L–Rh Pt Bi
Calibration 0.001–2.5 mg/L
72Ge (germanium) 159Tb (terbium)
89Y (yttrium) 163Dy (dysprosium)
105Pd (palladium) 165Ho (holmium)
115In (indium) 166Er (erbium)
139La (lanthanum) 169Tm (thulium)
140Ce (cerium) 172Yb (ytterbium)
141Pr
(praseodymium)
175Lu (lutetium)
146Nd (neodymium) 178Hf (hafnium)
147Sm (samarium) 197Au (gold)
153Eu (europium) 232Th (thorium)
Method 6 (1 element) Normal mode 9Be (beryllium) Urine samples diluted 10-fold.
Diluent:
1% v/v nitric acid (Romil, UpATM ultra purity acid),
Internal standards:
3 mg/L–Ge
Calibration 0.002–0.2 mg/L
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tuned on a daily basis to ensure optimisation.
Creatinine was determined by an automated alkaline picrate
method (Cocker et al., 2011), using an ABX Pentra 400 spectropho-
tometer (HORIBA ABX UK, Northampton, UK). An internal QC
material made from a pooled urine sample and stored frozen in
1 mL aliquots was used. The QC sample was thawed at room
temperature before use and analysed after each calibration. All QC
results fell within the acceptable range.
2.5. Quality control
Where available, certiﬁed reference materials (CRMs) were
analysed at the start and end of each analytical run, and again
after every 20 samples. Certiﬁed reference materials used wereClinChek levels 1 and 2 (lot 923 Recipe, Germany) for all elements
except for beryllium which used ClinChek levels 1 and 2 (lot
122 Recipe, Germany). In addition Lypocheck, urine metals Level 1
(lot 69141 Bio-Rad Laboratories, Hemel Hempstead, UK) was used
for mercury and those elements analysed in CCT mode elements
for which these CRMs were used are stated in Table 2. For
elements where no CRM was available, a blank urine sample
(from another unexposed source) was spiked with that element
and kept frozen at 20 C (as well as a portion of the blank
sample) until ready for analysis to be used as internal quality
control (these are referred to as ‘pool samples’ in Table 2). The
samples diluted with hydrochloric acid as per Method 4 (Ag, Ir,
Nb, Os, Pt, Rh, Ru, Ta and Te) had pool samples spiked at two
different concentrations (50 ng/L and 200 ng/L). Rarer elements
(Au, Ce, Dy, Er, Eu, Gd, Hf, Ho, In, La, Lu, Nd, Pr, Sm, Tb, Tm, Th, Y
Table 2
Quality control data and external quality assurance scheme information for the 61 elements analysed by six different ICP–MS methods.
Element Reference material used Blank urine used for
spike (if analysed)
mean  SD
Pool sample low spike
or Level 1 CRM
mean  SD
Pool sample high spike
or Level 2 CRM
mean  SD
% spiked recovery for pooled
spike samples or daily spiked
samples
External quality
assurance
certiﬁcation
Ag 50 ng/L pool sample low
spike
200 ng/L pool sample high
spike
1.6  2.6 ng/L (n = 36) 50 ng/L low spike
29.8  6.2 ng/L (n = 36)
200 ng/L high spike
133  10.8 ng/L (n = 36)
56.3% – 50 ng/L spike (n = 36)
65.7% – 200 ng/L spike (n = 36)
Al 10 mg/L daily spike
Clinchek Level 1: 71.6–
119 mg/L
Clinchek Level 2: 126–
188 mg/L
Clinchek 1
99.8  9.9 mg/L (n = 40)
Clinchek 2
157.0  14.0 mg/L
(n = 39)
105.7% – 10 mg/L daily spike
(n = 16)
G-EQUAS
As 2.5 mg/L daily spike
Biorad Level 1: 56–84 mg/L
Clinchek Level 1: 34.8–
52.2 mg/L
Clinchek Level 2: 65.7–
98.5 mg/L
Biorad 1
66.8  2.8 mg/L (n = 13)
Clincheck 1
41.1  2.4 mg/L (n = 25)
Clinchek 2
78.4  2.9 mg/L (n = 25)
103.3% – 2.5 mg/L daily spike
(n = 10)
TEQAS
Au 2.5 mg/L daily spike
1 mg/L pool sample spike
0.18  0.21 mg/L
(n = 10)
0.93  1.44 mg/L
(n = 10)
125.2% – 2.5 mg/L daily spike
(n = 31)
75.4% – 1 mg/L pool spike
(n = 10)
B 10 mg/L daily spike
100 mg/L pool sample spike
358.5  29.1 mg/L
(n = 14)
456.4  25.4 mg/L
(n = 14)
102.2% – 10 mg/L daily spike
(n = 16)
97.9% – 100 mg/L pool spike
(n = 14)
Ba 10 mg/L daily spike
10 mg/L pool sample spike
0.45  0.05 mg/L
(n = 14)
11.1  0.52 mg/L
(n = 14)
93.1% – 10 mg/L daily spike
(n = 16)
106.8% – 10 mg/L pool spike
(n = 14)
Be 200 ng/L daily spike
Clinchek Level 1: 36–66 ng/L
Clinchek Level 2: 198–
298 ng/L
Clinchek 1
58.2  2.4 ng/L (n = 23)
Clinchek 2
202.5  9.4 ng/L
(n = 23)
94.4% – 200 ng/L daily spike
(n = 34)
G-EQUAS
Bi 10 mg/L daily spike
1 mg/L pool sample spike
0.01  0.02 mg/L
(n = 14)
0.95  0.9 mg/L (n = 14) 87.2% – 10 mg/L daily spike
(n = 16)
94.3% – 1 mg/L pool spike
(n = 14)
Br 2.5 mg/L daily spike
100 mg/L pool sample spike
877.5  19.2 mg/L
(n = 12)
970.9  30.4 mg/L
(n = 12)
98.8% – 2.5 mg/L daily spike
(n = 10)
93.3% – 100 mg/L pool spike
(n = 12)
Cd 2.5 mg/L daily spike
Clinchek Level 1: 1.71–
2.57 mg/L
Clinchek Level 2: 12.0–
18.0 mg/L
Clinchek 1
1.91  0.16 mg/L
(n = 40)
Clinchek 2
13.3  0.8 mg/L (n = 39)
83.9% – 2.5 mg/L daily spike
(n = 16)
G-EQUAS &
TEQAS
Ce 2.5 mg/L daily spike
1 mg/L pool sample spike
0.0005  0.0007 mg/L
(n = 10)
1.08  0.37 mg/L
(n = 10)
109.9% – 2.5 mg/L daily spike
(n = 16)
108.4% – 1 mg/L pool spike
(n = 10)
Co 2.5 mg/L daily spike
Clinchek Level 1: 1.7–
2.56 mg/L
Clinchek Level 2: 27.7–
41.5 mg/L
Clinchek 1
1.89  0.12 mg/L
(n = 40)
Clinchek 2
31.3  1.5 mg/L (n = 39)
90.8% – 2.5 mg/L daily spike
(n = 16)
G-EQUAS &
TEQAS
Cr 2.5 mg/L daily spike
Biorad Level 1: 0.77–
2.43 mg/L
Clinchek Level 1: 7.88–
13.1 mg/L
Clinchek Level 2: 28.3–
42.5 mg/L
Biorad 1
2.4  0.4 mg/L (n = 13)
Clincheck 1
10.1  0.4 mg/L (n = 25)
Clinchek 2
34.2  1.1 mg/L (n = 25)
102.9% – 2.5 mg/L daily spike
(n = 10)
G-EQUAS &
TEQAS
Cs 1.5  0.1 mg/L (n = 14) 11.7  0.8 mg/L (n = 14)
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Table 2 (Continued)
Element Reference material used Blank urine used for
spike (if analysed)
mean  SD
Pool sample low spike
or Level 1 CRM
mean  SD
Pool sample high spike
or Level 2 CRM
mean  SD
% spiked recovery for pooled
spike samples or daily spiked
samples
External quality
assurance
certiﬁcation
10 mg/L daily spike
10 mg/L pool sample spike
94.1% – 10 mg/L daily spike
(n = 16)
102% – 10 mg/L pool spike
(n = 14)
Cu 2.5 mg/L daily spike
Clinchek Level 1: 48.6–
73 mg/L
Clinchek Level 2: 94.4–
142 mg/L
Clinchek 1
59.0  3.0 mg/L (n = 40)
Clinchek 2
111.9  6.2 mg/L
(n = 39)
87.4% – 2.5 mg/L daily spike
(n = 16)
G-EQUAS &
TEQAS
Dy 2.5 mg/L daily spike
1 mg/L pool sample spike
0.01  0.0007 mg/L
(n = 10)
1.12  0.37 mg/L
(n = 10)
108.7% – 2.5 mg/L daily spike
(n = 31)
111.6% – 1 mg/L pool spike
(n = 10)
Er 2.5 mg/L daily spike
1 mg/L pool sample spike
unspiked and spiked (at
1 mg/L)
0.0003  0.0005 mg/L
(n = 10)
1.10  0.37 mg/L
(n = 10)
108.1% – 2.5 mg/L daily spike
(n = 31)
110.1% – 1 mg/L pool spike
(n = 10)
Eu 2.5 mg/L daily spike
1 mg/L pool sample spike
0.01  0.002 mg/L
(n = 10)
1.09  0.37 mg/L
(n = 10)
108.6% – 2.5 mg/L daily spike
(n = 31)
108.8% – 1 mg/L pool spike
(n = 10)
Ga 2.5 mg/L daily spike 108.1% – 2.5 mg/L daily spike
(n = 31)
Gd 2.5 mg/L daily spike
1 mg/L pool sample spike
0.0007  0.0007 mg/L
(n = 10)
1.042  0.35 mg/L
(n = 10)
96.0% – 2.5 mg/L daily spike
(n = 31)
104.1% – 1 mg/L pool spike
(n = 10)
Ge 2.5 mg/L daily spike 106.9% – 2.5 mg/L daily spike
(n = 31)
Hf 2.5 mg/L daily spike
1 mg/L pool sample spike
0.08  0.11 mg/L
(n = 10)
1.29  0.49 mg/L
(n = 10)
103.1% – 2.5 mg/L daily spike
(n = 31)
120.8% – 1 mg/L pool spike
(n = 10)
Hg Clinchek Level 1: 2.79–
4.19 mg/L
Biorad Level 1: 20.7–
42.1 mg/L
Clinchek 1
3.1  0.2 mg/L (n = 37)
Clinchek 2
30.1  6.4 mg/L (n = 37)
G-EQUAS &
TEQAS
Ho 2.5 mg/L daily spike
1 mg/L pool sample spike
0.0004  0.0005 mg/L
(n = 10)
1.10  0.37 mg/L
(n = 10)
108.2% – 2.5 mg/L daily spike
(n = 31)
109.8% – 1 mg/L pool spike
(n = 10)
In 2.5 mg/L daily spike
1 mg/L pool sample spike
0.01  0.002 mg/L
(n = 10)
1.12  0.37 mg/L
(n = 10)
101.5% – 2.5 mg/L daily spike
(n = 31)
112.1% – 1 mg/L pool spike
(n = 10)
Ir 50 ng/L pool sample low
spike
200 ng/L pool sample high
spike
1.4  0.4 ng/L (n = 36) 50 ng/L low spike
46.7  1.6 ng/L (n = 36)
200 ng/L high spike
186.5  14.6 ng/L
(n = 36)
90.5% – 50 ng/L spike (n = 36)
92.5% – 200 ng/L spike (n = 36)
La 2.5 mg/L daily spike
1 mg/L pool sample spike
0.0005  0.0005 mg/L
(n = 10)
1.10  0.37 mg/L
(n = 10)
110.8% – 2.5 mg/L daily spike
(n = 31)
110.4% – 1 mg/L pool spike
(n = 10)
Li 10 mg/L daily spike
10 mg/L pool sample spike
5.0  0.21 mg/L (n = 14) 16.18  0.65 mg/L
(n = 14)
100.6% – 10 mg/L daily spike
(n = 16)
111% – 10 mg/L pool spike
(n = 14)
Lu 2.5 mg/L daily spike
1 mg/L pool sample spike
0.01  0.0003 mg/L
(n = 10)
1.095  0.37 mg/L
(n = 10)
96.0% – 2.5 mg/L daily spike
(n = 31)
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Table 2 (Continued)
Element Reference material used Blank urine used for
spike (if analysed)
mean  SD
Pool sample low spike
or Level 1 CRM
mean  SD
Pool sample high spike
or Level 2 CRM
mean  SD
% spiked recovery for pooled
spike samples or daily spiked
samples
External quality
assurance
certiﬁcation
109.5% – 1 mg/L pool spike
(n = 10)
Mn 2.5 mg/L daily spike
Biorad Level 1: 0.77–
2.43 mg/L
Clinchek Level 1: 2.46–
3.68 mg/L
Clinchek Level 2: 17–
25.4 mg/L
Biorad Level 1
7.9  0.3 mg/L (n = 13)
Clinchek 1
21.0  1.02 mg/L
(n = 25)
Clinchek 2
19.18  0.42 mg/L
(n = 25)
103% – 2.5 mg/L daily spike
(n = 10)
G-EQUAS &
TEQAS
Mo 2.5 mg/L daily spike
Clinchek Level 1: 21.8–
32.6 mg/L
Clinchek Level 2: 87.2–
131 mg/L
Clinchek 1
26.8  2.8 mg/L (n = 25)
Clinchek 2
103.7  8.3 mg/L
(n = 25)
107.3% – 2.5 mg/L daily spike
(n = 10)
Nb 50 ng/L pool sample low
spike
200 ng/L pool sample high
spike
2.0  0.9 ng/L (n = 36) 50 ng/L low spike
45.3  5.9 ng/L (n = 36)
200 ng/L high spike
181.8  5.7 ng/L
(n = 36)
86.5% – 50 ng/L spike (n = 36)
89.9% – 200 ng/L spike (n = 36)
Nd 2.5 mg/L daily spike
1 mg/L pool sample spike
0.0009  0.001 mg/L
(n = 10)
1.10  0.37 mg/L
(n = 10)
108.7% – 2.5 mg/L daily spike
(n = 31)
110.1% – 1 mg/L pool spike
(n = 10)
Ni 2.5 mg/L daily spike
Clinchek Level 1: 4.14–
6.9 mg/L
Clinchek Level 2: 33.1–
55.1 mg/L
Clinchek 1
6.0  0.51 mg/L (n = 40)
Clinchek 2
41.4  2.2 mg/L (n = 39)
89.1% – 2.5 mg/L daily spike
(n = 16)
G-EQUAS &
TEQAS
Os 50 ng/L pool sample low
spike 200 ng/L pool sample
high spike
0.2  0.1 ng/L (n = 36) 50 ng/L low spike
51.8  2.2 ng/L (n = 36)
200 ng/L high spike
208.0  4.0 ng/L
(n = 36)
103.3% – 50 ng/L spike (n = 36)
103.9% – 200 ng/L spike
(n = 36)
Pb 2.5 mg/L daily spike
Clinchek Level 1: 18.5–
30.8 mg/L
Clinchek Level 2: 48.4–
80.6 mg/L
Clinchek 1
21.4  1.8 mg/L (n = 40)
Clinchek 2
56.0  5.5 mg/L (n = 39)
91.0% – 2.5 mg/L daily spike
(n = 16)
G-EQUAS &
TEQAS
Pd 2.5 mg/L daily spike
Clinchek Level 1: 1.17–
2.17 mg/L
Clinchek Level 2: 6.9–
12.8 mg/L
Clinchek 1
1.7  0.3 mg/L (n = 23)
Clinchek 2
10.5  2.1 mg/L (n = 23)
97.4% – 2.5 mg/L daily spike
(n = 31)
Pr 2.5 mg/L daily spike
1 mg/L pool sample spike
0.01  0.0005 mg/L
(n = 10)
1.10  0.37 mg/L
(n = 10)
108.8% – 2.5 mg/L daily spike
(n = 31)
109.7% – 1 mg/L pool spike
(n = 10)
Pt 50 ng/L pool sample low
spike
200 ng/L pool sample high
spike
Clinchek Level 1: 31–47 ng/L
Clinchek Level 2: 91–137 ng/
L
1.5  1.6 ng/L (n = 36) Clinchek 1
36.4  3.2 ng/L (n = 25)
50 ng/L low spike
42.3  2.5 ng/L (n = 36)
Clinchek 2
100.6  5.8 ng/L
(n = 25)
200 ng/L high spike
168.4  5.4 ng/L
(n = 36)
81.7% – 50 ng/L spike (n = 36)
83.5% – 200 ng/L spike (n = 36)
G-EQUAS
Rb 2.5 mg/L daily spike
100 mg/L pool sample spike
541.1  34.9 mg/L
(n = 14)
640.8  42.7 mg/L
(n = 14)
120.7% – 2.5 mg/L daily spike
(n = 16)
99.6% – 100 mg/L pool spike
(n = 14)
Rh 50 ng/L pool sample low
spike
200 ng/L pool sample high
spike
1.3  0.8 ng/L (n = 36) 50 ng/L low spike
47.2  1.9 ng/L (n = 36)
200 ng/L high spike
183.3  6.0 ng/L
(n = 36)
91.8% – 50 ng/L spike (n = 36)
91.0% – 200 ng/L spike (n = 36)
Ru 50 ng/L pool sample low
spike
9.0  3.8 ng/L (n = 36) 50 ng/L low spike
54.8  3.0 ng/L (n = 36)
200 ng/L high spike
192.1  7.5 ng/L
(n = 36)
91.6% – 50 ng/L spike (n = 36)
91.6% – 200 ng/L spike (n = 36)
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Table 2 (Continued)
Element Reference material used Blank urine used for
spike (if analysed)
mean  SD
Pool sample low spike
or Level 1 CRM
mean  SD
Pool sample high spike
or Level 2 CRM
mean  SD
% spiked recovery for pooled
spike samples or daily spiked
samples
External quality
assurance
certiﬁcation
200 ng/L pool sample high
spike
Sb 2.5 mg/L daily spike
Clinchek Level 1: 9.44–
14.2 mg/L
Clinchek Level 2: 36.7–
55.1 mg/L
Clinchek 1
11.5  0.7 mg/L (n = 40)
Clinchek 2
45.2  2.5 mg/L (n = 39)
91.8% – 2.5 mg/L daily spike
(n = 16)
G-EQUAS
Sc 10 mg/L daily spike
0.1 mg/L pool sample spike
0.89  0.18 mg/L
(n = 14)
0.98  0.18 mg/L
(n = 14)
93.9% – 10 mg/L daily spike
(n = 16)
85.6% – 0.1 mg/L pool spike
(n = 14)
Se 2.5 mg/L daily spike
Clinchek Level 1: 22.6–
34 mg/L
Clinchek Level 2: 61.2–
91.8 mg/L
Clinchek 1
26.3  2.0 mg/L (n = 25)
Clinchek 2
63.3  6.7 mg/L (n = 25)
95.2% – 2.5 mg/L daily spike
(n = 10)
G-EQUAS &
TEQAS
Sm 2.5 mg/L daily spike
1 mg/L pool sample spike
0.0008  0.001 mg/L
(n = 10)
1.10  0.37 mg/L
(n = 10)
110% – 2.5 mg/L daily spike
(n = 31)
110.0% – 1 mg/L pool spike
(n = 10)
Sn Clinchek Level 1: 3.94–
5.9 mg/L
Clinchek Level 2: 7.54–
11.3 mg/L
Clinchek 1
4.8  0.5 mg/L (n = 25)
Clinchek 2
9.47  0.6 mg/L (n = 25)
97.2% – 2.5 mg/L daily spike
(n = 10)
Sr 10 mg/L daily spike
100 mg/L pool sample spike
16.8  0.6 mg/L (n = 14) 123.0  4.5 mg/L
(n = 14)
80.6% – 10 mg/L daily spike
(n = 16)
106.1% – 100 mg/L pool spike
(n = 14)
Ta 50 ng/L pool sample low
spike
200 ng/L pool sample high
spike
23.4  9.0 ng/L (n = 36) 50 ng/L low spike
66.4  10.1 ng/L
(n = 36)
200 ng/L high spike
194.9  18.0 ng/L
(n = 36)
85.9% – 50 ng/L spike (n = 36)
85.7% – 200 ng/L spike (n = 36)
Tb 2.5 mg/L daily spike
1 mg/L pool sample spike
0.01  0.0005 mg/L
(n = 10)
1.10  0.37 mg/L
(n = 10)
107.4% – 2.5 mg/L daily spike
(n = 31)
109.9% – 1 mg/L pool spike
(n = 10)
Te 50 ng/L pool sample low
spike
200 ng/L pool sample high
spike
16.8  7.1 ng/L (n = 36) 50 ng/L low spike
49.0  8.6 ng/L (n = 36)
200 ng/L high spike
143.9  14.4 ng/L
(n = 36)
64.5% – 50 ng/L spike (n = 36)
63.6% – 200 ng/L spike (n = 36)
Th 2.5 mg/L daily spike
1 mg/L pool sample spike
0.01  0.04 mg/L
(n = 10)
1.09  0.37 mg/L
(n = 10)
105.6% – 2.5 mg/L daily spike
(n = 31)
108.6% – 1 mg/L pool spike
(n = 10)
Ti 2.5 mg/L daily spike
10 mg/L pool sample spike
2.2  0.4 mg/L (n = 12) 12.3  0.2 mg/L (n = 12) 107.4% – 2.5 mg/L daily spike
(n = 10)
101.3% – 10 mg/L pool spike
(n = 12)
Tl 2.5 mg/L daily spike
Clinchek Level 1: 5.82–
8.74 mg/L
Clinchek Level 2: 15–
22.6 mg/L
Clinchek 1
7.0  0.5 mg/L (n = 40)
Clinchek 2
18.0  1.1 mg/L (n = 39)
95.6% – 2.5 mg/L daily spike
(n = 16)
G-EQUAS &
TEQAS
Tm 2.5 mg/L daily spike
1 mg/L pool sample spike
0.01  0.0004 mg/L
(n = 10)
1.10  0.37 mg/L
(n = 10)
107.3% – 2.5 mg/L daily spike
(n = 1)
110.2% – 1 mg/L pool spike
(n = 10)
V 2.5 mg/L daily spike
Clinchek Level 1: 15.9–
23.9 mg/L
Clinchek 1
21.0  1.02 mg/L
(n = 25)
Clinchek 2
50.1  1.7 mg/L (n = 25)
105.9% – 2.5 mg/L daily spike
(n = 10)
G-EQUAS
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Table 2 (Continued)
Element Reference material used Blank urine used for
spike (if analysed)
mean  SD
Pool sample low spike
or Level 1 CRM
mean  SD
Pool sample high spike
or Level 2 CRM
mean  SD
% spiked recovery for pooled
spike samples or daily spiked
samples
External quality
assurance
certiﬁcation
Clinchek Level 2: 38.7–
58.1 mg/L
W 2.5 mg/L daily spike
1 mg/L pool sample spike
0.67  0.58 mg/L
(n = 12)
1.77  0.58 mg/L
(n = 12)
110.2% – 2.5 mg/L daily spike
(n = 10)
110% – 1 mg/L pool spike
(n = 12)
G-EQUAS
Y 2.5 mg/L daily spike
1 mg/L pool sample spike
0.01  0.03 mg/L
(n = 10)
1.16  0.38 mg/L
(n = 10)
117.6% – 2.5 mg/L daily spike
(n = 31)
115.3% – 1 mg/L pool spike
(n = 10)
Yb 2.5 mg/L daily spike
1 mg/L pool sample spike
0.01  0.0005 mg/L
(n = 10)
1.09  0.37 mg/L
(n = 10)
105.9% – 2.5 mg/L daily spike
(n = 31)
109.3% – 1 mg/L pool spike
(n = 10)
Zn 2.5 mg/L daily spike
Clinchek Level 1: 177–
295 mg/L
Clinchek Level 2: 445–
667 mg/L
Clinchek 1
217.6  18.9 mg/L
(n = 40)
Clinchek 2
508.7  27.1 mg/L
(n = 39)
84.7% – 2.5 mg/L daily spike
(n = 16)
TEQAS
Zr 10 mg/L daily spike
1 mg/L pool sample spike
0.5  0.2 mg/L (n = 14) 1.3  0.3 mg/L (n = 14) 97% – 10 mg/L daily spike
(n = 16)
85.4% – 1 mg/L pool spike
(n = 14)
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one concentration (between 0.1 and 100 mg/L depending on the
likely abundance found in a urine sample). In addition to these
prepared pool samples, freshly prepared daily spiked samples
were also analysed for all elements except mercury (Method 3)
and those analysed in an hydrochloric acid diluent (Method 5). An
aqueous check standard was also analysed at the start and end of
each analytical run and after every ten samples (except for
mercury analysis). Participation in external quality assurance
schemes was also undertaken both in the UK TEQAS organised by
the University of Surrey and the German G-EQUAS, organised by
University of Erlangen (elements where quality assurance
certiﬁcation was achieved are stated in Table 2). Participation
in external quality assurance schemes for creatinine measure-
ments was also undertaken in a UK scheme (RIQAS organised by
Randox Laboratories Limited, Belfast, N. Ireland).
2.6. Limits of detection and limits of quantiﬁcation
The limit of detection (LOD) for each analyte was calculated as
three times the standard deviation of the blanks run throughout all
analyses. The limit of quantiﬁcation (LOQ) in this report is
calculated as the LOQ in an undiluted urine sample and can be
deﬁned as three times the standard deviation of all of the blank
samples run throughout the analyses (i.e. the LOD) multiplied by
the dilution factor of the urine sample (which varied from 10 to 20),
i.e. this is the lowest quantiﬁable concentration measured in a
urine sample (Table 3).
2.7. Statistical methods and mathematical modelling
For some elements, a proportion of the measurements fell below
the LOQ. Such measurements are referred to as left censored.
A common method of dealing with left-censored measurements is to
substitute in the value of half the LOQ, however this method lacks
rigour and can lead to biased estimates of the true variability of themeasurements. Bayesian methods have gained popularity in recent
years and can handle censored data more naturally than classical
likelihood-based methods. As such, a Bayesian approach using
Markov Chain Monte Carlo (Gilks et al., 1996) has been used for
dealing with the censored data.
It is common practice in biological monitoring to adjust the
urinary concentrations for dilution. Statistical modelling allows
the investigation of the effectiveness of this correction. One such
approach is to compare the estimates of variability that arise from
modelling corrected and uncorrected concentrations; for elements
where the variability decreases with creatinine correction, the
correction may be beneﬁcial. As repeat samples were taken on
some individuals thus resulting in correlation between their
measurements, a mixed effects model was used in the analysis to
account for correlation and to model inter-individual variability via
random effects. The urinary concentrations were assumed to be
lognormally distributed, as is common in biomonitoring (Leese
et al., 2013).
The effects of smoking and gender were considered, resulting in
a mixed effects model of the form:
lnðYijÞ ¼ m þ bgIg;ij þ bsIs;ij þ wi þ eij
wi  Nð0; s21Þ
eij  Nð0; s22Þ
where the elemental urinary concentration (either creatinine-
corrected or uncorrected) is denoted by Yij, (the subscripts denote
the jth measurement on the ith subject). These elemental
concentrations (on the log scale) are expressed as a sum of ﬁxed
effects, random effects and residual error; m represents the mean
concentration of a female non-smoker, Ig,ij and Is,ij are indicator
variables which take the value 1 if the individual is a male and a
smoker respectively. bg and bs are corrections to the overall mean
and measure consistent differences between genders and smoking
status. The random effects wi are assumed to be normally
distributed with a mean of zero and standard deviation s21, with
s21 quantifying the inter-individual variability. The term eij
represents the residual errors which are assumed to be normally
Table 3
A summary of the 61 elemental concentrations and the creatinine corrected concentrations all the group and for males and females. Concentrations that were <LOQ were
replaced by 1/2 LOQ. For elements where the majority of concentrations were <LOQ, 95th percentiles were calculated using an additional two methods; one where
concentrations <LOQ were replaced by zero, and another by the LOQ. These give lower and upper bounds of the 95th percentiles respectively, and are presented in brackets.
Element LOQ in mg/L in undiluted
urine
%<
LOQ
All (n = 132) conc. in
mg/L
All (n = 132) conc. in mmol/mol
creatinine
Females (n = 50) conc. in mmol/
mol creatinine
Males (n = 82) conc. in mmol/
mol creatinine
Median 95th
percentile
Median 95th percentile Median 95th percentile Median 95th percentile
Ag 0.029 97 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
Al 1.312 24 3.83 25.73 18.48 215.19 20.97 298.28 17.66 129.90
As 0.094 1 10.48 152.40 19.07 254.43 18.09 188.50 19.27 264.06
Au 9.42 98 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
B 5.764 0 0.83a 2.34a 11.29b 26.96b 14.26b 30.88b 9.52b 23.95b
Ba 0.273 8 1.37 8.42 1.40 5.92 1.63 5.92 1.34 5.94
Be 0.0006 3 0.0052 0.0116 0.077 0.221 0.089 0.261 0.075 0.200
Bi 0.175 96 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
Br 15.603 0 2.35a 5.43a 4.26b 9.04b 4.59b 9.85b 4.16b 7.74b
Cd 0.08 32 0.13 0.52 0.17 0.57 0.19 0.65 0.16 0.42
Ce 0.005 83 <LOQ 0.008 <LOQ 0.0122 [0.0061,0.023] <LOQ 0.0143 [0.0057,0.027] <LOQ 0.0081
[0.0061,0.015]
Co 0.078 11 0.22 1.04 0.50 2.47 0.74 2.61 0.42 1.97
Cr 0.148 16 0.35 0.79 0.92 2.85 1.18 4.64 0.84 2.04
Cs 0.085 0 4.22 9.30 4.41 9.23 4.91 10.67 4.03 7.61
Cu 0.504 0 8.75 19.33 18.66 35.41 21.31 43.85 17.37 27.97
Dy 0.005 100 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
Er 0.0003 90 <LOQ 0.001 <LOQ 0.0008 [0.0006,
0.0012]
<LOQ 0.0011
[0.0010,0.0016]
<LOQ 0.0006
[0.0006,0.0008]
Eu 0.014 100 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
Ga 0.051 29 0.08 0.33 0.17 0.47 0.19 0.48 0.16 0.44
Gd 0.009 93 <LOQ 0.0220 <LOQ 0.029 [0.020,0.051] <LOQ <LOQ <LOQ 0.059 [0.059,0.061]
Ge 0.221 11 0.65 2.62 1.2 3.2 1.2 3.7 1.2 3.0
Hf 0.64 89 <LOQ 0.99 <LOQ 1.35 [0.75,2.47] <LOQ 1.52 [0.63,2.93] <LOQ 0.98 [0.79,1.64]
Hg 0.094 2 0.43 2.81 0.38 1.43 0.46 2.00 0.34 1.16
Ho 0.0001 73 <LOQ 0.001 <LOQ 0.0010
[0.0010,0.0010]
<LOQ 0.0010
[0.0010,0.0010]
<LOQ 0.0010
[0.0010,0.0010]
In 0.031 98 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
Ir 0.007 85 <LOQ 0.01 <LOQ 0.014 [0.006,0.026] <LOQ 0.018 [0.007,0.033] <LOQ 0.009 [0.006,0.015]
La 0.0008 42 0.001 0.004 0.0008 0.0040 0.0010 0.0054 0.0007 0.003
Li 0.139 0 0.011a 0.0284a 0.22b 0.52b 0.29b 0.63b 0.20b 0.46b
Lu 0.0001 96 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
Mn 0.092 66 <LOQ 0.46 <LOQ 1.31 [1.31,1.58] <LOQ 1.86 [1.86,2.03] <LOQ 0.75 [0.75,0.88]
Mo 0.701 0 29.13 107.25 39.91 106.48 43.61 110.07 38.41 106.48
Nb 0.025 100 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
Nd 0.007 99 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
Ni 0.271 4 1.99 6.35 5.01 10.66 5.61 11.67 4.61 9.62
Os 0.004 100 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
Pb 0.116 20 0.47 7.63 0.31 4.07 0.26 1.26 0.33 8.80
Pd 0.588 87 <LOQ 0.91 <LOQ 1.96 [0.75, 3.68] <LOQ 2.26 [0.84,4.51] <LOQ 1.30 [0.75,2.18]
Pr 0.003 100 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
Pt 0.005 92 <LOQ 0.01 <LOQ 0.009 [0.003, 0.017] <LOQ 0.011 [0.004,0.022] <LOQ 0.005 [0.002,0.010]
Rb 0.57 0 1.09a 2.70a 1.75b 3.83b 1.99b 4.46b 1.65b 3.60b
Rh 0.0007 3 0.004 0.013 0.005 0.016 0.006 0.031 0.005 0.012
Ru 0.0009 0 0.02 0.07 0.027 0.076 0.033 0.091 0.025 0.061
Sb 0.092 80 <LOQ 0.26 <LOQ 0.32 [0.24,0.57] <LOQ 0.32 [0.149,0.641] <LOQ 0.28 [0.274,0.450]
Sc 0.187 0 2.55 5.88 7.78 18.53 9.69 20.77 7.10 14.24
Se 0.822 0 13.40 33.39 21.73 42.18 23.49 42.18 20.98 39.93
Sm 0.006 99 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
Sn 0.227 38 0.33 2.44 0.42 2.03 0.55 2.72 0.33 1.62
Sr 0.612 0 0.08a 0.35a 0.14b 0.49b 0.17b 0.93b 0.12b 0.33b
Ta 0.019 14 0.04 0.10 0.032 0.078 0.038 0.105 0.029 0.064
Tb 0.003 100 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
Te 0.012 7 0.05 0.15 0.058 0.117 0.065 0.135 0.053 0.107
Th 0.538 94 <LOQ 0.62 <LOQ 0.83 [0.27,1.52] <LOQ <LOQ <LOQ 0.54 [0.292,0.946]
Ti 0.835 5 5.14 12.19 13.82 33.62 16.09 51.51 12.77 26.92
Tl 0.098 27 0.17 0.44 0.11 0.26 0.13 0.29 0.11 0.23
Tm 0.0002 95 <LOQ <LOQ <LOQ <LOQ <LOQ 0.0003 <LOQ <LOQ
V 0.128 0 1.58 3.79 4.59 10.69 5.17 13.35 4.39 9.32
W 0.208 11 1.44 6.04 1.27 3.79 1.48 4.12 1.17 3.03
Y 0.059 100 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
Yb 0.0003 89 <LOQ 0.001 <LOQ 0.00088
[0.00083,0.00125]
<LOQ 0.00077
[0.00074,0.00129]
<LOQ 0.0012
[0.0012,0.0012]
Zn 7.018 0 0.18a 0.73a 0.42b 1.08b 0.38b 1.00b 0.42b 1.11b
Zr 0.945 96 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 0.19
a Conc. in mg/L.
b mmol/mol creatinine.
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deviation s22, with s
2
2 quantifying intra-individual variability.
The models were ﬁtted using Markov Chain Monte Carlo
(MCMC) methods in WinBUGs (Lunn et al., 2000), within a
Bayesian framework. For elements where a large proportion of
measurements fall below the LOQ, the mixed effects modelling
may result in biased estimates of the ﬁxed effects and variability.
Although there is no standard cut-off point, the decision was thus
made to limit the mixed effects analysis to only those elements
where no more than one third of measurements fall below the LOQ
to minimise the bias arising from censored data.
3. Results
All urine samples were analysed by each of the six ICP–MS
methods and the summarised results are presented in Table 3. Each
method used different quality control approaches and these are
summarised below.
3.1. Quality control
3.1.1. External
All elements determined in the CRMs were found to be within
the acceptable range for each analyte. The CRMs used, the ranges
and results are presented in Table 2. Generally the standard
deviations of the analytes in CRM samples were less than 10%.
Successful participation in external quality assurance schemes
was obtained for all 18 elements for which the schemes were
available. The schemes are stated for each of these elements in
Table 2.
3.1.2. Internal
Analyte concentrations of the rarer elements in internally
prepared QC materials showed variation in recoveries. For the
elements that were analysed with hydrochloric acid diluent
(Method 4) the recoveries varied in the prepared frozen spiked
pool samples, with low values for silver (56% for 50 ng/L spike
and 66% for 200 ng/L spike) to good spiked recoveries for
osmium (103.3% for 50 ng/L spike and 103.9% for 200 ng/L spike).
For rare elements diluted with nitric acid (Method 5) recoveries
ranged from 75.4% for gold and 120.8% recovery for hafnium. In
addition, these elements were also analysed with samples
containing daily prepared spikes, which gave an over recovery
for gold of 125.2 and 103.1% for hafnium. It should be noted
that no storage or stability tests had been undertaken on the
in-house frozen pool samples and it is likely that both the silver
and gold were not stable throughout the freeze/thaw process.
The standard 2.5 mg/L check analysed throughout the silver and
gold analysis showed good stability and accuracy. For the
elements measured using Method 1 that did not have a CRM
material (B, Ba, Br, Cs, Li, Rb, Sc and Zr) the recoveries of the
frozen pool spiked samples were better, ranging from a lower
recovery of 85 and 86% for zirconium and scandium respectively
(spiked at 1 mg/L for Zr and 0.1 mg/L for Sc) to 111% for lithium
spiked at 10 mg/L. For the elements measured using Method
2 elements that did not have a CRM material (Br, Ti and W) the
recoveries ranged from 93% for bromine (spiked at 100 mg/L) to
110% for tungsten (spiked at 1 mg/L).
3.2. Summary of the data
3.2.1. Sample cohort
In total 280 urine samples were collected from 132 subjects.
Samples provided came from 82 males (180 samples) and 50 females
(100 samples). The known ages of these adults ranged from 18 to66 years). The 14 smokers made up 10.6% of the people who provided
samples and 7.5% of the total number of samples. Subjects provided
between one and nine samples each, with 65 subjects providing one
sample, and two subjects providing nine samples.
3.2.2. Sample results
Creatinine levels were statistically signiﬁcantly higher in
males than in females (p < 0.001), lying within the range
0.76–22.20 mmol/L in females, and 1.32–32.63 mmol/L in males.
Although creatinine is known to decrease with age (Cocker et al.,
2011), no signiﬁcant trends with age were found but this may be
due to the relatively small sample size. A large proportion of
creatinine concentrations in females (33%) were found to be below
3 mmol/L but only 6% of creatinine concentrations in males were
below this value. The proportion of women with lower creatinine
values is higher in our cohort than in than the 9% female workers
reported by Cocker et al. (2011). This is most likely due to the socio-
economic differences between females in the general population
and females from chemically exposed workplaces. In the reporting
of the creatinine corrected values in this study no samples have
been excluded; creatinine concentrations were not an exclusion
criterion.
A summary of all of the data from the analysis of the 280
samples are shown in Table 3. Table 3 lists the concentration of the
elements in both mg/L and creatinine corrected as mmol/mol
creatinine with the median and the 95th percentile being listed in
both units, based on up to nine repeat samples per person. Male
and female data are reported in creatinine corrected units only.
For around half of the elements, over 50% of measurements
were greater than the LOQ, for 16 elements (Ag, Au Bi, Dy, Eu, In, Lu,
Nb, Nd, Os, Pr, Sm, Tb, Tm, Y, and Zr), >95% of measurements were
greater than the LOQ.
Table 4 compares the uncorrected and creatinine corrected
values from this study for all samples with values obtained in three
other studies.
3.2.3. Mixed effects modelling
For 30 elements (Ag, Au, Bi, Ce, Dy, Er, Eu, Gd, Hf, Ho, In, Ir, La, Lu,
Mn, Nb, Nd, Os, Pd, Pr, Pt, Sb, Sm, Sn, Tb, Th, Tm, Y, Yb and Zr) over a
third of samples were below the LOQ. Thus mixed effects modelling
was not carried out on these elements due to the bias that may arise
from the large proportion of censored measurements.
For the other 31 elements, the mixed effects modelling takes
into account the repeat samples made on individuals and whilst
doing so, creatinine corrected levels were found to be signiﬁcantly
higher in females than males for B, Be, Co, Cs, Cu, Hg, Li, Ni, Rb, Ru,
Sc, Se, Sr, Ti and V. As discussed earlier, creatinine was found to be
signiﬁcantly higher in males than females, thus these observed
gender effects may partly be due to the creatinine correction. For
all the aforementioned elements apart from Co and Hg, uncorrect-
ed levels were found to be signiﬁcantly higher in males; for
uncorrected Co and Hg, no signiﬁcant gender effects were found.
Signiﬁcantly higher corrected concentrations were found in
smokers than non-smokers for Cd only (geometric mean of
1.41 vs 0.85 mmol/mol creatinine, an increase of 65%), but
signiﬁcantly lower were found for B only in smokers than non-
smokers (geometric mean of 0.72 vs 0.53 mmol/mol creatinine, a
decrease of 27%.
The intra-individual and inter-individual geometric coefﬁcients
of variation (GCVintra and GCVinter) are indications of the extent of
variability within and between individuals in relation to the mean,
for lognormally distributed data. Correcting forcreatinine resultedin
either a signiﬁcant reduction in GCVintra (B, Ba, Cd, Co, Cs, Cu, Ga, Ge,
Hg, Li, Mo, Ni, Rb, Rh, Sc, Se, Sr, Te, Ti, Tl, W and Zn), or no signiﬁcant
difference in GCVintra (Al, As, Be, Br, Cr, La, Pb, Ru, Ta and V),
demonstrating that creatinine correction may be effective in
Table 4
Comparison of the elemental concentrations from this study with other published data.
Element
All (n = 132)
conc. in mg/L
All (n = 132)
conc. in mmol/mol
creatinine
Hoet et al., 2013 NHANES, 2011
4th report
data 2009–10
(for adults over 20 year)
Fréry et al., 2011
France
data collected 2006–7
Median 95th
percentile
Median 95th
percentile
Median 95th percentile Median 95th percentile Median 95th percentile
Ag <LOQ <LOQ <LOQ <LOQ
Al 3.83 25.73 17.66 215.19 2.17 mg/L
(8.54 mmol/
mol)
9.27mg/L
(31.4 mmol/
mol)
As total 10.48 152.40 19.07 254.43 14.1 mg/L
(20.7 mmol/
mol)
157 mg/L
(208.1 mmol/
mol)
8.75 mg/L
(13.17 mmol/
mol)
93.1 mg/L
(131.7 mmol/mol)
12.68 mg/L
(16.17 mmol/
mol)
72.75 mg/L
(92.44 mmol/
mol)
Au <LOQ <LOQ <LOQ <LOQ
B 0.83a 2.34a 11.29b 26.96b
Ba 1.37 8.42 1.40 5.92 1.91 mg/L
(1.53 mmol/mol)
6.97mg/L
(4.94 mmol/
mol)
1.43 mg/L
(1.20 mmol/
mol)
6.80 mg/L (4.96 mmol/
mol)
Be 0.0052 0.0117 0.077 0.221 <LOD <0.007 mg/L <LOD <LOD
Bi <LOQ <LOQ <LOQ <LOQ <LOD 0.03 mg/L
(0.54 mmol/
mol)
Br 2.35a 5.43a 4.26b 9.04b
Cd 0.13 0.52 0.15 0.57 0.28 mg/L
(0.24 mmol/
mol)
1.06 mg/L
(0.84 mmol/
mol)
0.23 mg/L
(0.23 mmol/
mol)
1.13 mg/L (1.02 mmol/
mol)
0.32 mg/L
(0.29 mmol/
mol)
0.95 mg/L
(0.91 mmol/mol)
Ce <LOQ 0.0080 <LOQ 0.0148
Co 0.22 1.04 0.49 2.47 0.18 mg/L
(0.38 mmol/
mol)
1.003 mg/L
(1.65 mmol/
mol)
0.35 mg/L
(0.65 mmol/
mol)
1.35 mg/L (2.47 mmol/
mol)
0.22 mg/L
(0.36 mmol/
mol)
1.4 mg/L
(2.17 mmol/mol)
Cr 0.35 0.79 0.91 2.85 0.13 mg/L
(0.24 mmol/
mol)
0.45 mg/L
(0.59 mmol/
mol)
0.19 mg/L
(0.36 mmol/
mol)
0.65 mg/L
(1.17 mmol/mol)
Cs 4.22 9.30 4.41 9.23 4.49 mg/L
(3.64 mmol/
mol)
11.1 mg/L (8.33 mmol/
mol)
Cu 8.75 19.33 18.66 35.41 8.18 mg/L
(12.43 mmol/
mol)
19.6 mg/L
(21.0 mmol/
mol)
Dy <LOQ <LOQ <LOQ <LOQ
Er <LOQ 0.001 <LOQ 0.00092
Eu <LOQ <LOQ <LOQ <LOQ
Ga 0.08 0.33 0.15 0.44
Gd <LOQ 0.0220 <LOQ 0.035
Ge 0.65 2.62 1.2 3.2
Hf <LOQ 0.99 <LOQ 1.61
Hg 0.43 2.81 0.38 1.43 0.38 mg/L
(0.17 mmol/mol)
1.88 mg/L
(0.95 mmol/
mol)
0.45 mg/L
(0.25 mmol/
mol)
2.53 mg/L (1.21 mmol/
mol)
Ho <LOQ 0.001 <LOQ 0.001
In <LOQ <LOQ <LOQ <LOQ <LOD <0.02
Ir <LOQ 0.01 <LOQ 0.016
La 0.0010 0.004 0.0005 0.0039
Li 0.0110a 0.0284a 0.22b 0.52b 22.9 mg/L
(349.9 mmol/
mol)
75 mg/L
(1.22 mmol/
mol)
Lu <LOQ <LOQ <LOQ <LOQ
Mn <LOQ 0.46 <LOQ 1.45 <LOD 0.355 mg/L
(0.84 mmol/
mol)
Mo 29.13 107.25 39.91 106.48 31.3 mg/L
(35.1 mmol/mol)
116 mg/L
(90.6 mmol/
mol)
42 mg/L
(48.53 mmol/
mol)
144 mg/L
(149.6 mmol/mol)
Nb <LOQ <LOQ <LOQ <LOQ
Nd <LOQ <LOQ <LOQ <LOQ
Ni 1.99 6.35 5.01 10.66 2.05 mg/L
(3.45 mmol/
mol)
4.73mg/L
(8.22 mmol/
mol)
1.50 mg/L
(2.50 mmol/
mol)
4.54 mg/L
(7.26 mmol/mol)
Os <LOQ <LOQ <LOQ <LOQ
Pb 0.47 7.63 0.31 4.07 0.87 mg/L
(0.97mmol/
mol)
2.81 mg/L
(1.2 mmol/mol)
0.49 mg/L
(0.27 mmol/
mol)
1.71 mg/L (0.86 mmol/
mol)
Pd <LOQ 0.91 <LOQ 2.22 <LOD 0.128 mg/L
(0.09 mmol/
mol)
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Table 4 (Continued)
Element
All (n = 132)
conc. in mg/L
All (n = 132)
conc. in mmol/mol
creatinine
Hoet et al., 2013 NHANES, 2011
4th report
data 2009–10
(for adults over 20 year)
Fréry et al., 2011
France
data collected 2006–7
Median 95th
percentile
Median 95th
percentile
Median 95th percentile Median 95th percentile Median 95th percentile
Pr <LOQ <LOQ <LOQ <LOQ
Pt <LOQ 0.01 <LOQ 0.01 <LOD <0.06 mg/L <LOD 0.017 mg/L
(0.02 mmol/mol
creatinine)
Rb 1.09a 2.70a 1.75b 3.83b
Rh 0.004 0.013 0.005 0.016
Ru 0.02 0.07 0.027 0.076
Sb <LOQ 0.26 <LOQ 0.404 0.04 mg/L
(0.04 mmol/
mol)
0.236 mg/L
(0.14 mmol/
mol)
0.05 mg/L
(0.05 mmol/
mol)
0.22 mg/L (0.18 mmol/
mol)
0.09 mg/L
(0.07 mmol/
mol)
0.32 mg/L
(0.23 mmol/mol)
Sc 2.55 5.88 7.78 18.53
Se 13.40 33.39 21.73 42.18 25.1 mg/L
(30.91 mmol/
mol)
61.6 mg/L
(47.7 mmol/
mol)
Sm <LOQ <LOQ <LOQ <LOQ
Sn 0.33 2.44 0.30 2.03 0.37 mg/L
(0.33 mmol/
mol)
2.54 mg/L
(1.74 mmol/
mol)
0.59 mg/L
(0.50 mmol/
mol)
2.81 mg/L
(2.17 mmol/mol)
Sr 0.08a 0.35a 0.14b 0.49b
Ta 0.04 0.10 0.030 0.078
Tb <LOQ <LOQ <LOQ <LOQ
Te 0.05 0.15 0.057 0.117 0.15 mg/L
(0.12 mmol/mol)
0.358 mg/L
(0.30 mmol/
mol)
Th <LOQ 0.62 <LOQ 0.89
Ti 5.14 12.19 13.82 33.62
Tl 0.17 0.44 0.10 0.25 0.21 mg/L
(0.10 mmol/mol)
0.5 mg/L
(0.22 mmol/
mol)
0.16 mg/L
(0.08 mmol/
mol)
0.41 mg/L (0.20 mmol/
mol)
Tm <LOQ <LOQ <LOQ <LOQ
V 1.58 3.79 4.59 10.69 0.25 mg/L
(0.49 mmol/
mol)
1.083 mg/L
(2.77 mmol/
mol)
1.01 mg/L
(1.92 mmol/mol)
2.79 mg/L
(6.21 mmol/mol)
W 1.44 6.04 1.27 3.79 0.08 mg/L
(0.04 mmol/
mol)
0.37 mg/L (0.21 mmol/
mol)
Y <LOQ 0.03 <LOQ <LOQ
Yb <LOQ 0.001 <LOQ 0.001
Zn 0.18a 0.73a 0.42b 1.08b 256 mg/L
(424.99 mmol/
mol)
1.05 mg/L
(1.08 mmol/
mol)
Zr <LOQ <LOQ <LOQ <LOQ
a Conc. in mg/L.
b mmol/mol creatinine.
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urine dilution.
Table 5 presents the GCVintra and GCVinter for the 31 elements
for which mixed effects modelling was carried out. After adjusting
for variation due to gender and smoking, the elements that
displayed the greatest GCVintra were Pb (137%), Al (121%) and As
(84%). Those that displayed the lowest were Cu (22%), Se (22%), Cs
(24%), B (26%) and Co (26%). In terms of variability between
individuals, GCVinter was once again greatest for Pb (235%), As
(156%) and Al (131%), and lowest for Sc (25%), Ti (27%) and Se (29%).
Thus of all the 31 elements for which mixed effects modelling was
carried out, Pb displayed the greatest total variation (total
GCV = 423%), and Se the lowest (total GCV 37%).
4. Discussion
This study presents data for the urinary levels of 61 elements in
an occupationally unexposed adult UK population. The referenceranges have been presented as 95th percentile levels, which is the
same approach as the German Human Biomonitoring Commission
(Institut für Arbeitsschutz der Deutschen Gesetzlichen Unfallver-
sicherung, 2012) and the NHANES study (NHANES, 2011) in the US.
The data can be directly compared with these studies and with the
recent Belgian study by Hoet et al. (2013). This study has reported
both creatinine uncorrected and creatinine corrected concentra-
tions; no values have been excluded from the data presented. One
additional characteristic of this study is that measurements were
obtained from the same individuals. This data has been modelled
to give an estimation of variation both between individuals and
within the same individual. This has allowed us to quantify
variation in elemental concentrations within individuals (intra-
individual variation), which would not have been possible had just
one sample been provided. In addition, the variation between
individuals (inter-individual variation) can be quantiﬁed via the
random effects speciﬁcation. One source of intra-individual
variation that arises is the variation in the dilution of urine, which
Table 5
Geometric intra-individual and inter-individual coefﬁcient of variation (GCV) for the 31 elements for which mixed effects modelling was carried out (adjusted for gender and
smoking).
GCVinter (%) GCVinter,corrected (%) GCVintra (%) GCVintra,corrected (%)
Al 127 131 137 121
As 161 156 106 84
B 52 45 53 26
Ba 114 90 67 50
Be 44 38 42 53
Br 59 37 49 44
Cd 69 50 68 48
Co 75 62 55 26
Cr 66 73 39 44
Cs 49 33 46 24
Cu 52 34 44 22
Ga 85 52 47 27
Ge 71 34 61 44
Hg 95 77 59 41
Li 45 35 50 29
Mo 75 55 74 51
Ni 71 39 61 41
Pb 251 235 158 137
Rb 44 32 59 37
Rh 71 55 55 38
Ru 65 45 49 46
Sc 41 25 46 35
Se 58 29 48 22
Sr 77 58 52 35
Ta 46 44 33 38
Te 57 36 57 37
Ti 50 27 70 49
Tl 55 43 48 31
V 62 49 37 41
W 129 121 66 50
Zn 71 50 62 41
J. Morton et al. / Toxicology Letters 231 (2014) 179–193 191explains why applying a creatinine correction to account for
dilution led to either a reduction or no signiﬁcant difference in
intra-individual variability in all of the elements for which mixed
effects modelling was carried out. As an example, the intra-
individual coefﬁcient of variation for creatinine-corrected copper
was around half that of uncorrected copper (45 vs 21%). Thus
accounting for dilution via a creatinine correction has been shown
to be effective in explaining some of the variation.
The analytical methods used in this study were ‘tailored’ to the
elements being measured and this allowed the quantiﬁcation of
some elements that would be difﬁcult in a large multi-elemental
analysis. This study attempted to analyse the samples using routine
methods that would be carried out in a single analysis or common
group of elements. Beryllium and mercury are two elements that
have speciﬁcally beneﬁted from single analysis for each element. In
addition elements like platinum, tellurium and tantalum have
beneﬁted from being analysed in a hydrochloric acid matrix. This
tailored approach has allowed 95th percentiles to be established
for both beryllium and platinum and this has not always been the
case in other larger studies that have measured these elements
(Hoet et al., 2013; NHANES, 2011). However, a multi-elemental
analysis undertaken by Heitland and Köster (2006) measuring
23 elements in one analysis reported both beryllium and platinum
results that compare well with the values found in this study. Gold
and silver are unstable analytes when spiked into solutions and
this leads to poor recoveries and so without established QC
materials more work is required with these methods and their
stability in frozen samples, however, the results for both elements
showed that 97–98% of the samples were below the LOQ. It is also
evident from the number of elements for which there is no CRM
and EQA schemes that there is a need to add/include further
elements in these CRMs and EQA schemes. In-house prepared pool
urine samples spiked with known concentrations of these
elements, whilst the best available approach currently, do notsatisfactorily address the quality control for such a wide number of
elements.
Total arsenic was measured in this study within Method 2 in
collision cell mode. However, as arsenic is highly inﬂuenced by
dietary factors it would not normally be measured this way in our
laboratory; instead a speciation analysis would be undertaken
using a liquid chromatography ICP–MS method (Leese et al., 2013).
The total values have been reported in this study so that
comparisons with other studies can be made.
Overall it was possible to assign 95th percentile values for 45 of
the elements measured in the urine samples (Table 3). The other
16 elements, Ag, Au Bi, Dy, Eu, In, Lu, Nb, Nd, Os, Pr, Sm, Tb, Tm, Y,
and Zr all exhibited too high a percentage of results below the limit
of detection. This is still useful information because it is now
known that these elements are low in urine samples from
occupationally unexposed individuals and are not yet detectable
with our existing methodologies. Comparing the data obtained
from this studies from with Belgium (Hoet et al., 2013), France
(Fréry et al., 2011) and US (NHANES, 2011) studies show that this
study reports 95th percentiles for 20 elements (B, Br, Ce, Er, Ga, Gd,
Ge, Hf, Ho, Ir, La, Rb, Rh, Ru, Sc, Sr, Ta, Th, Ti and Yb) and < LOQ for
14 elements (Ag, Au, Dy, Eu, Lu, Nb, Nd, Os, Pr, Sm, Tb, Tm, Y and Zr)
that have not been reported before in any of the other studies. The
95th percentiles established in this study were compared in Table 4
with those obtained from larger European and US based studies
which were more comprehensive studies in terms of demo-
graphics, sample numbers and sample collection information.
Data from a smaller UK based study (White and Sabbioni, 1998)
has also been used to compare this current UK data with. White
and Sabbioni published their study in 1998 where urine samples
from a similar UK population to this study were measured for
thirteen elements as part of a larger EU study (White and Sabbioni,
1998). Comparing the results obtained in this study with those
reported in 1998 showed that similar values were obtained for
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values were obtained for cobalt, copper, mercury, selenium and
thallium and slightly higher values obtained for chromium in this
study. In addition, this study showed considerably lower 95th
percentile values for cadmium, lead and manganese from those
reported in the White and Sabbioni study; with urinary cadmium
decreasing from 2.1 to 0.6 mmol/mol creatinine, urinary lead
decreasing from 27.2 to 4.1 mmol/mol creatinine and urinary
manganese decreasing from 3.1 to 1.3 mmol/mol creatinine. In the
UK leaded petrol was removed from sale by the year 2000 and so it
is likely that the decrease in urinary lead levels are as a direct result
of this as evidenced by a similar reduction in the lead although at
lower concentrations in the US NHANES study, where the levels
decreased from 1.26 to 0.86 mmol/mol creatinine from 1999–2000
to 2009–2010 (NHANES, 2011).
In comparing the data in Table 4 the 95th percentiles obtained
for antimony (Hoet et al., 2013; Fréry et al., 2011; NHANES, 2011),
barium (Hoet et al., 2013; NHANES, 2011), caesium (NHANES,
2011), cobalt (Hoet et al., 2013; Fréry et al., 2011; NHANES, 2011),
manganese (Hoet et al., 2013), mercury (Hoet et al., 2013; NHANES,
2011), molybdenum (Hoet et al., 2013; NHANES, 2011), thallium
(Hoet et al., 2013; NHANES, 2011), tin (Hoet et al., 2013; Fréry et al.,
2011) and zinc (Hoet et al., 2013) exhibit very similar values across
the different studies and this could mean that differences such as
diet and environmental factors have less of an effect for these
elements. Some elements such as antimony, cobalt and tin
compare very well across all the studies. Whereas the 95th
percentiles for aluminium, chromium, copper, lead, nickel,
palladium, vanadium and tungsten are higher in this study than
those published by the Belgian or US studies. The median levels of
aluminium, boron, copper and nickel compare well with a UK
study by Sieniawska et al. where urine samples were collected
from 111 patients from a renal stones clinic (Sieniawska et al.,
2012). Sieniawska et al. (2012) report higher levels of cadmium,
cobalt, manganese, lead tin and tungsten and lower levels of
chromium mercury and vanadium than those in this study. A major
difference in UK samples is seen in the higher levels of vanadium
(10.7 mmol/mol creatinine reported here compared to 2.8 mmol/
mol creatinine in Belgium and 6.2 mmol/mol creatinine in France),
tungsten (3.8 mmol/mol creatinine reported here compared to
0.4 mmol/mol creatinine in US) and lead (4.07 mmol/mol creatinine
reported here compared to 1.2 mmol/mol creatinine in Belgium
and 0.9 mmol/mol creatinine in US). Differences are also seen with
lower 95th percentile levels in the UK samples for cadmium,
lithium, selenium and tellurium. Differences that occur with UK
levels for elements such as tungsten require further investigation.
Recent publications have highlighted a higher risk of stroke
associated with elevated tungsten exposures (Tyrrell et al., 2013).
Interestingly if the 95th percentiles established in this study
are compared to those published by the German Federal
Environmental Agency (Institut 638 für Arbeitsschutz der Deut-
schen Gesetzlichen Unfallversicherung, 2012) as RV95 values then
the uncorrected for creatinine 95th percentiles for nickel and
mercury here are higher in this study. For nickel the RV95 is 3 mg/L
we report a 95th percentile of 6.35 mg/L and for mercury the
RV95 is 1 mg/L we report a 95th percentile of 2.8 mg/L. For
cadmium and thallium the levels reported here are lower than the
RV95 values and the platinum levels are the same at 10 ng/L. It
must be remembered that the RV95 values do not correct for
creatinine and therefore comparisons are likely to be more
susceptible to variations.
Mixed effect analysis was carried out on 31 elements where no
more than a third of concentrations were below the LOQ. The
mixed effect analysis showed that, for all of the elements for
which mixed effects analysis was carried out, applying a
creatinine correction to the data in all cases gave either areduction in intra-individual variability (for B, Ba, Cd, Co, Cs, Cu,
Ga, Ge, Hg, Li, Mo, Ni, Rb, Rh, Sc, Se, Sr, Te, Ti, Tl, W and Zn), or no
signiﬁcant difference in variability (Al, As, Be, Br, Cr, Pb, Ru, Ta and
V).
The element that displayed the greatest creatinine-corrected
variation in relation to the mean (in terms of GCV) was lead. In fact,
lead displayed the greatest inter-individual GCV and intra-individual
GCV of the 31 elements. Creatinine-corrected boron, cobalt, caesium,
copper and selenium displayed the lowest intra-individual GCV,
indicating that day-to-day variation of these elements in individuals
are low in comparison to the other elements (after adjusting for
gender). These elements are considered ‘essential’ elements and it is
likely that the smaller variation is as a result of regulation of these
elements in the body. When inter-individual variation was
investigated, scandium, selenium and titanium were found to
exhibit the lowest inter-individual GCV, indicating that creatinine-
corrected concentrations of these elements varied least between
individuals (after adjusting for gender), of the 31 elements.
For those elements where a reduction in variability was seen,
creatinine correction may be beneﬁcial. The effectiveness of
creatinine correction was investigated further by ﬁtting a mixed
effects model to uncorrected data (on the natural log scale) with ln
(creatinine) treated as a ﬁxed effect in the model. For some
elements, the coefﬁcients for ln(creatinine) were not found to be
signiﬁcantly different from the value 1 and there was no signiﬁcant
difference in the within-person variability when compared to
when using the creatinine-corrected data (Al, As, Ba, Cd, Co, Ga, Ge,
Mo, Ni, Pb, Zn). For these elements, this result indicated that the
creatinine corrected values were effective in reducing some of the
variation in elemental concentrations due to urine dilution.
For Be, Br, Cr, Ru, Ta and V, although there was no signiﬁcant
difference in GCVintra between the corrected and uncorrected data,
a signiﬁcant reduction was seen in the model where ln(creatinine)
was treated as a ﬁxed effect with an estimated coefﬁcient. This is
analogous to adjusting for creatinine by dividing the elemental
concentrations by a power (the estimated coefﬁcient) of creatinine.
The statistical analysis showed that this led to signiﬁcantly lower
intra-individual variation for those elements than both corrected
and uncorrected concentrations.
5. Conclusions
The 95th percentiles of 61 elements in urine samples have been
reported. Elements for which we have reported 95th percentile
values but for which there is no available comparison are Br, Ce, Er,
Ga, Gd, Ge, Hf, Ho, Ir, La, Rb, Rh, Ru, Sc, Sr, Ta, Th, Ti and Yb.
The mixed effect modelling provides valuable information on
the variation of elemental concentrations by accounting for
correlations between repeat samples and modelling the intra-
individual and inter-individual variability. Creatinine adjustment
of analyte concentrations was found to be beneﬁcial for
22 elements: B, Ba, Cd, Co, Cs, Cu, Ga, Ge, Hg, Li, Mo, Ni, Rb, Rh,
Sc, Se, Sr, Te, Ti, Tl, W and Zn. For the remaining nine elements (Al,
As, Be, Br, Cr, Pb, Ru, Ta and V), no signiﬁcant change in intra-
individual variability was found.
There is a need for a more comprehensive study. This study is
limited by its small size and the restricted demographics of the of
the sample cohort. However, it does mostly agree well with
ﬁndings from other larger studies. Elements like antimony, cobalt,
thallium and tin have similar values across all the studies. There
appear to be some elemental differences speciﬁc to the UK data;
cadmium and lithium levels are lower than in other studies and
chromium, lead, vanadium and tungsten levels are higher. This
ﬁnding warrants further investigation.
Technological advances and the increase in recycling rates
mean that exposure to rarer elements will likely increase. There is a
J. Morton et al. / Toxicology Letters 231 (2014) 179–193 193need for other researchers to establish levels of rarer elements in
biological samples and a need for quality control material with a
wider range of elemental concentrations to ensure the quality and
comparability of the different studies. The approach of this study
has provided information on the variation of elemental concen-
trations both within and between individuals. This study has also
reported levels for the largest number of elements analysed in a UK
study of this type.
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